Pipeline
VX-01
VX-01 is a humanized monoclonal antibody designed to be used with antifungal agents to treat lethal mucormycosis. VX-01 halts progression of infection through prevention of angioinvasion, and enhancing immune regognition of invading fungal cells.
VX-01 Notable Publications: https://doi.org/10.1126/scitranslmed.ads7369, https://doi.org/10.1126/sciadv.aaw1327, https://doi.org/10.1172/JCI71349, https://www.jci.org/articles/view/73585
VXV-01
VXV-01 is a dual antigen vaccine targeting hospital-acquired infections caused by multidrug resistant Candida albicans, Candida auris, and Gram-negative bacteria including those caused by Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.
VXV-01 Notable Publications: https://doi.org/10.1038/s41598-025-32488-8, https://doi.org/10.1093/cid/ciy185
VXD-01
VXD-01 is a rapid LAMP diagnostic test for the detection of Mucormycosis infection. Current available diagnostics are inaccurate and too time consuming for the rapid progression of this disease.
VXD-01 Notable Publications: https://journals.asm.org/doi/10.1128/jcm.01790-25